Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Polo-like kinase 1 (PLK1) is a key regulator of the cell-cycle progression found in human cancers, and a potential therapeutic target for oncology drug development. The recent journal Clinical Cancer Research details the Phase 1b Study of Onvansertib in combination with chemotherapy+bevacizumab treatment for patients with patients with KRAS-mutated metastatic colorectal cancer (mCRC).
Cardiff Oncology’s novel inhibitor, Onvansertib effectively targets PLK1, that prevents from tumor cell growth. It aids restore DNA damage and promote the efficacy of the standard of care therapy in a number of indications.
Search 
+86 21 5895 0110 
